Literature DB >> 16239061

No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer.

Ian G Campbell1, Diana M Eccles, David Y H Choong.   

Abstract

A functional T to G germline polymorphism in the promoter region of MDM2 (SNP309) has been reported to profoundly accelerate tumor formation suggesting that it may also represent a powerful cancer predisposing allele. To investigate the role of SNP309 in cancer predisposition we undertook a case-control study of this polymorphism among 351 women diagnosed with breast cancer, 302 women diagnosed with ovarian and 258 female controls from a British population. The GG genotype was not associated with either breast cancer (OR 1.04, 95% CI 0.67-1.60) or ovarian cancer (OR 0.86, 95% CI 0.53-1.37). This study has found no evidence that the GG genotype of the MDM2 SNP309 polymorphism is associated with early onset or familial breast cancer or with ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16239061     DOI: 10.1016/j.canlet.2005.09.003

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  25 in total

1.  Individual and combined effects of MDM2 SNP309 and TP53 Arg72Pro on breast cancer risk: an updated meta-analysis.

Authors:  Hongtao Cheng; Biao Ma; Ran Jiang; Wei Wang; Hui Guo; Na Shen; Dapeng Li; Qunzi Zhao; Rui Wang; Pengfei Yi; Yue Zhao; Zeming Liu; Tao Huang
Journal:  Mol Biol Rep       Date:  2012-06-24       Impact factor: 2.316

2.  ARLTS1, MDM2 and RAD51 gene variations are associated with familial breast cancer.

Authors:  Elif Akisik; Hulya Yazici; Nejat Dalay
Journal:  Mol Biol Rep       Date:  2010-04-01       Impact factor: 2.316

3.  MDM2 SNP309 polymorphism and breast cancer risk: a meta-analysis.

Authors:  Erjiang Zhao; Dan Cui; Ling Yuan; Weiquan Lu
Journal:  Mol Biol Rep       Date:  2011-07-03       Impact factor: 2.316

4.  Association of p73 gene G4C14-A4T14 polymorphism and MDM2 gene SNP309 with non-small cell lung cancer risk in a Chinese population.

Authors:  Wen Li; Shuang Shuang Wang; Jing Deng; Jian Xin Tang
Journal:  Oncol Lett       Date:  2017-06-07       Impact factor: 2.967

5.  A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer.

Authors:  Hongmei Nan; Abrar A Qureshi; David J Hunter; Jiali Han
Journal:  Cancer Causes Control       Date:  2008-09-24       Impact factor: 2.506

6.  Have the roles of two functional polymorphisms in breast cancer, R72P in P53 and MDM2-309 in MDM2, become clearer?

Authors:  Rodney J Scott
Journal:  Breast Cancer Res       Date:  2010-02-03       Impact factor: 6.466

Review 7.  Role of genetic polymorphisms and ovarian cancer susceptibility.

Authors:  Peter A Fasching; Simon Gayther; Leigh Pearce; Joellen M Schildkraut; Ellen Goode; Falk Thiel; Georgia Chenevix-Trench; Jenny Chang-Claude; Shan Wang-Gohrke; Susan Ramus; Paul Pharoah; Andrew Berchuck
Journal:  Mol Oncol       Date:  2009-02-04       Impact factor: 6.603

8.  Murine double-minute 2 homolog single nucleotide polymorphism 309 and the risk of gynecologic cancer.

Authors:  Masatsugu Ueda; Michiko Yamamoto; Osamu Nunobiki; Eisaku Toji; Naomi Sato; Shinji Izuma; Yoshiaki Okamoto; Kiyo Torii; Sadamu Noda
Journal:  Hum Cell       Date:  2009-05       Impact factor: 4.174

9.  No association of MDM2 SNP309 with risk of glioblastoma and prognosis.

Authors:  Soufiane El Hallani; Yannick Marie; Ahmed Idbaih; Mathieu Rodero; Blandine Boisselier; Florence Laigle-Donadey; François Ducray; Jean-Yves Delattre; Marc Sanson
Journal:  J Neurooncol       Date:  2007-06-14       Impact factor: 4.130

10.  Results based on 124 cases of breast cancer and 97 controls from Taiwan suggest that the single nucleotide polymorphism (SNP309) in the MDM2 gene promoter is associated with earlier onset and increased risk of breast cancer.

Authors:  Ying-Fang Sun; Jyh-Der Leu; Su-Mei Chen; I-Feng Lin; Yi-Jang Lee
Journal:  BMC Cancer       Date:  2009-01-13       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.